Nov 17, 2019

Sirio Pharma and Kerry Group Form Ground-Breaking Agreement for Probiotic Gummies

Asia, Europe & The United States, 17 November, 2019: Sirio Pharma (300791) announces the signing of Probiotic Strategy Cooperation Agreement (BC30) with the Kerry Group. The collaboration was confirmed at Sirio’s China Research and Development Center in Shantou, Guangdong and is expected to harness the huge growth opportunity in China’s emerging probiotic gummy sector.

Asia, Europe & The United States, 17 November, 2019: Sirio Pharma (300791) announces the signing of Probiotic Strategy Cooperation Agreement (BC30) with the Kerry Group. The collaboration was confirmed at Sirio’s China Research and Development Center in Shantou, Guangdong and is expected to harness the huge growth opportunity in China’s emerging probiotic gummy sector.

The partnership will see Sirio’s use its 20+ year pedigree in researching and developing nutraceutical products, along with its advanced technologies – including the combination of Bacillus Coagulans GBI-6086, a probiotic starting material, into gummy products.

The Kerry Group is a globally recognized provider of high-quality raw starting materials in the field of food and nutrition, with a reputation for innovating technologies and creating new trends in healthy lifestyles. Its Bacillus Coagulans GBI-6086 is widely used in the European and American markets thanks to the probiotic’s high degree of stability – its clinical benefits to intestinal and immune health have been tested and approved in several countries.

The signing of the agreement marks a milestone in the in-depth cooperation between the two companies. Through the comprehensive collaboration of raw materials, formula development, flavoring and process techniques, bespoke gummy products designed specifically to demands of customers in China will be launched.

In recent years, China has experienced a huge surge in demand for nutrition and health products, and this partnership is established at the ideal time to capitalize on the expanding market. The initial partnership will cover nutritional gummies, but will also extend into a diverse range of technological innovations, with the ambitions of launching a number of new products in to China and internationally. A key driver of both companies is to expand consumer options in health and nutrition.

Company profile

The contract manufacturer in compliance with the worldwide up-to-date GMP standard for all dietary supplements including softgel, capsule, tablet, powder, gummy vitamins and oral liquid